THOUSAND OAKS, Calif.,
Oct. 14, 2016 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) today announced the appointment of Ellen J. Kullman to the Amgen Board of
Directors, effective Oct. 14,
2016. Ms. Kullman will serve as a member of the Audit
Committee and the Governance and Nominating Committee of the Board.
Following the appointment of Ms. Kullman, the Board will comprise
14 directors, 13 of whom are independent.
"We are pleased to welcome Ellen Kullman to the
Amgen Board," said Robert A.
Bradway, chairman and chief executive officer of Amgen.
"Ellen's deep experience in high-technology global businesses with
strong regulatory oversight will be invaluable to Amgen as we grow
our business and pursue our mission to serve patients."
Ms. Kullman, 60, is the former president, chair and chief
executive officer of E.I. du Pont de Nemours and Company, or
DuPont, a science and technology-based company, where she served
from January 2009 to October 2015. Prior to this, Ms. Kullman served
as president of DuPont from October
2008 to January 2009. From
June 2006 through September 2008, she served as executive vice
president. Prior to that, Ms. Kullman was group vice president,
DuPont Safety and Protection. Ms. Kullman has been a director of
United Technologies Corporation, a technology products and services
company, since 2011, serving on its Committee on Compensation and
Executive Development and chairing its Committee on Governance and
Public Policy. Ms. Kullman served as a director of General Motors,
from 2004 to 2008, serving on its Audit Committee.
Ms. Kullman has also served as a director of Carbon3D, Inc., a
privately-held 3D printing company, since April 2016. Ms. Kullman has served on the Board
of Trustees of Tufts University since
2006 and on the Board of Overseers of Tufts
University School of Engineering since 2006. She
served as chair of the US-China Business Council from 2013 to 2015.
In 2016, Ms. Kullman joined the board of directors of Dell
Technologies, a privately-held technology company, and the Temasek
Americas Advisory Panel of Temasek Holdings (Private) Limited, a
privately-held investment company based in Singapore. Ms. Kullman received a bachelor of
science in mechanical engineering degree from Tufts University and a master's degree from the
Kellogg School of Management at Northwestern
University.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Trish Hawkins, 805-447-5631
(media)
Arvind Sood, 805-447-1060
(investors)
Logo -
http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-announces-appointment-of-ellen-j-kullman-to-board-of-directors-300345263.html
SOURCE Amgen